Fierce Biotech

‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E

First poo transplant to treat food allergy in people has ‘exciting’ results

Amgen drops ph. 1 obesity drug, upping pressure on MariTide

Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline

5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

FDA Panel Votes In Favor of Replimune’s Melanoma Treatment

9 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues

9 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial

5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard

GSK is implementing a $2.5 billion, three-year restructuring initiative to prioritize late-stage drug development and reorganize its research operations.

MapLight shares sink on mixed ph. 2 schizophrenia readout

7 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Argenx to Buy Forte Biosciences for $2.2 Billion

8 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout

6 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data

5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

‘Too Rare to Care’? A New Center for Rare Diseases Hopes to Change That

Bristol Myers says it will build pharma's 'most powerful' AI supercomputer with Nvidia

Bristol Myers Squibb is partnering with Nvidia to build what it describes as the most powerful AI supercomputer in the life sciences industry.

Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive

10 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Nobel Laureate Jennifer Doudna enters AI protein design arena

4 news sources are covering this Science story right now — Newsylist is tracking how fast it spreads.

Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market

CEPI-backed Ebola vaccine set to enter phase 1 trials

An experimental Alzheimer's drug shows some promise as researchers hunt new approaches

Researchers and investors are evaluating new clinical data from Biogen as the firm explores tau-targeting treatments for Alzheimer’s disease.

All eyes on data on Biogen’s tau therapy

4 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors

Q32 Bio shares see significant gains following the release of positive 36-week trial data for its experimental alopecia areata drug, Bempikibart.

FDA releases 14 drug rejection letters after 3-month pause

FDA resumes releasing drug rejection letters after 3-month pause

'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretive

6 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization

5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback

Eli Lilly's market capitalization has risen following a setback for Kailera's oral GLP-1 obesity drug trials in China.

Two tests GPs can soon offer to help spot endometriosis

New diagnostic technologies recommended by NICE may soon allow GPs to identify endometriosis, potentially slashing long wait times for patients.

Novartis to Buy Myricx Bio for Up to $1.5 Billion

Novartis is expanding its cancer-drug pipeline through the acquisition of U.K.-based biotech firm Myricx Bio in a deal valued up to $1.5 billion.

Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial

Roche's drug candidate divarasib outperformed rival therapies in a Phase 3 trial for KRAS-driven lung cancer.

FDA’s top gene therapy regulator is leaving his role

French biotech stock soars 34% after new data on experimental medicine

Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases

Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion

French biotech Ipsen is acquiring Kartos Therapeutics in a deal valued at up to $1.75 billion to expand its hemato-oncology pipeline.

BIO 2026: How a gut feeling transformed cancer treatment forever

Ophthalmology venture grabs investors’ attention, raises $330 million

US provides Ebola treatment for outbreak in Congo, bringing trials closer

US provides experimental Ebola treatment for Congo outbreak

Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers

Stock market today: Dow, S&P 500, Nasdaq futures plunge as Wall Street weighs US-Iran talks, AI trade

Wall Street is experiencing a volatile shift as a global tech sell-off and AI doubts clash with gains in healthcare and progress in US-Iran talks.

Closely watched Pfizer lung cancer drug falls short in clinical trial

HHS Launches Unprecedented Department-Wide Effort to Restore American Leadership in Clinical Trials

The U.S. Department of Health and Human Services is launching a department-wide effort to accelerate clinical trials and restore American leadership in medical research.